Other formats:
BibTeX
LaTeX
RIS
@proceedings{2247552,
author = {Behrens, Frank and Taylor, Peter and Mease, Philip J. and Peloso, Paul and Wetzel, Dieter and Brun, Nicolai and Wiens, Brian and BrandtandJuergens, Jan and Drescher, Edit and Dokoupilová, Eva and RowinskaandOsuch, Anna and AbdelandKader, Martin Nadia and de Vlam, Kurt},
keywords = {Izokibep; efficacy; psoriatic arthriris; clinical trial},
language = {eng},
title = {Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial},
url = {https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/},
year = {2022}
}
TY - CONF
ID - 2247552
AU - Behrens, Frank - Taylor, Peter - Mease, Philip J. - Peloso, Paul - Wetzel, Dieter - Brun, Nicolai - Wiens, Brian - Brandt-Juergens, Jan - Drescher, Edit - Dokoupilová, Eva - Rowinska-Osuch, Anna - Abdel-Kader, Martin Nadia - de Vlam, Kurt
PY - 2022
TI - Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial
KW - Izokibep
KW - efficacy
KW - psoriatic arthriris
KW - clinical trial
UR - https://acrabstracts.org/abstract/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini/
N2 - Psoriatic arthritis (PsA) is a chronic, inflammatory disease with multiple clinical manifestations (arthritis, spondylitis, enthesitis, dactylitis, skin, nails). IL-17 inhibitors have shown efficacy across all disease domains. Izokibep, a first-in-class fusion protein, is a unique IL-17A inhibitor with very high potency (Kd =0.3 pM), small molecular size (18.6 kD versus mAbs ~ 150 kD), and attachment to albumin. Treat to target is an important strategy to optimize disease control (reducing inflammation, limiting damage) as well as optimizing quality of life in PsA. Many composite measures of disease control have been proposed for clinical decision-making, including ACR scores, DAS28-CRP, DAPSA scores, and MDA. Here, we report the efficacy results of izokibep 40 mg Q2W and 80 mg Q2W versus placebo across a range of disease outcome measures as well as relevant safety data over 16 weeks compared to placebo.
ER -
BEHRENS, Frank, Peter TAYLOR, Philip J. MEASE, Paul PELOSO, Dieter WETZEL, Nicolai BRUN, Brian WIENS, Jan BRANDT-JUERGENS, Edit DRESCHER, Eva DOKOUPILOVÁ, Anna ROWINSKA-OSUCH, Martin Nadia ABDEL-KADER and Kurt DE VLAM. \textit{Achievement of Different Treatment Targets with Izokibep Demonstrates Efficacy Benefits in Patients with Active Psoriatic Arthritis: Results from a 16-Week Randomized, Placebo-Controlled Phase 2 Clinical Trial}. 2022. ISSN~2326-5191.
|
